GSK Flovent HFA approved

17 May 2004
News

Executive Summary

GlaxoSmithKline's CFC-free version of Flovent (fluticasone) for the treatment of asthma as prophylactic therapy in adults and adolescents 12 years and older clears FDA May 14. The drug is the second HFA nasal steroid to be approved after Aventis' Nasacort HFA inhaler for allergic rhinitis was cleared in April (1"The Pink Sheet" April 12, 2004, In Brief). A proposed rule on CFC-containing products is near publication (2"The Pink Sheet" April 26, 2004, In Brief)...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS043974

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS043974

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

GSK Flovent HFA approved

News

Executive Summary

Related Content

Aventis Nasacort HFA approved

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert